{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:00:43Z","timestamp":1789984843675,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40262-013-0111-4","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T08:52:51Z","timestamp":1384419171000},"page":"261-269","source":"Crossref","is-referenced-by-count":25,"title":["Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study"],"prefix":"10.1007","volume":"53","author":[{"given":"Jacqueline S. L.","family":"Kloth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Eechoute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline F.","family":"Samer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L. R.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Daali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bavanthi","family":"Balakrishnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof J.","family":"Bennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"111_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"111_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"111_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6:734\u201345.","journal-title":"Nat Rev Drug Discov"},{"key":"111_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313.","journal-title":"N Engl J Med"},{"key":"111_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25\u201335.","journal-title":"J Clin Oncol"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2005.08.035","volume":"42","author":"RH Mathijssen","year":"2006","unstructured":"Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer. 2006;42:141\u20138.","journal-title":"Eur J Cancer"},{"key":"111_CR7","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1200\/JCO.2011.38.2572","volume":"29","author":"RH Mathijssen","year":"2011","unstructured":"Mathijssen RH, Loos WJ, Verweij J. Determining the best dose for the individual patient. J Clin Oncol. 2011;29:4345\u20136.","journal-title":"J Clin Oncol"},{"key":"111_CR8","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","volume":"20","author":"BC Goh","year":"2002","unstructured":"Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20:3683\u201390.","journal-title":"J Clin Oncol"},{"key":"111_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/jnci\/djh298","volume":"96","author":"RH Mathijssen","year":"2004","unstructured":"Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585\u201392.","journal-title":"J Natl Cancer Inst"},{"key":"111_CR10","first-page":"237","volume":"60","author":"CB Eap","year":"2004","unstructured":"Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004;60:237\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"111_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clpt.2004.02.005","volume":"75","author":"M Wong","year":"2004","unstructured":"Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther. 2004;75:529\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"111_CR12","first-page":"650","volume":"9","author":"M Agrawal","year":"2003","unstructured":"Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res. 2003;9:650\u20136.","journal-title":"Clin Cancer Res"},{"key":"111_CR13","first-page":"369","volume":"38","author":"GD Luker","year":"1997","unstructured":"Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med. 1997;38:369\u201372.","journal-title":"J Nucl Med"},{"key":"111_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.clpt.2004.09.002","volume":"77","author":"M Wong","year":"2005","unstructured":"Wong M, Evans S, Rivory LP, et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther. 2005;77:33\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"111_CR15","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1200\/JCO.2005.02.1295","volume":"24","author":"M Wong","year":"2006","unstructured":"Wong M, Balleine RL, Blair EY, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol. 2006;24:2448\u201355.","journal-title":"J Clin Oncol"},{"key":"111_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP Erp van","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692\u2013706.","journal-title":"Cancer Treat Rev"},{"key":"111_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.108.024612","volume":"37","author":"S Shukla","year":"2009","unstructured":"Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37:359\u201365.","journal-title":"Drug Metab Dispos"},{"key":"111_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jpba.2009.10.020","volume":"51","author":"P Bruijn de","year":"2010","unstructured":"de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography\/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010;51:934\u201341.","journal-title":"J Pharm Biomed Anal"},{"key":"111_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/bmc.1576","volume":"25","author":"H Loor de","year":"2011","unstructured":"de Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1\u2032-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomed Chromatogr. 2011;25:1091\u20138.","journal-title":"Biomed Chromatogr"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"111_CR21","unstructured":"Beal SL. NONMEM users guides. Ellicott City: Icon Development Solutions; 1989."},{"key":"111_CR22","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","volume":"15","author":"BE Houk","year":"2009","unstructured":"Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497\u2013506.","journal-title":"Clin Cancer Res"},{"key":"111_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"111_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00280-008-0917-1","volume":"64","author":"JO Haznedar","year":"2009","unstructured":"Haznedar JO, Patyna S, Bello CL, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2009;64:691\u2013706.","journal-title":"Cancer Chemother Pharmacol"},{"key":"111_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJMra1010600","volume":"364","author":"L Wang","year":"2011","unstructured":"Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144\u201353.","journal-title":"N Engl J Med"},{"key":"111_CR26","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","volume":"27","author":"NP Erp van","year":"2009","unstructured":"van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009;27:4406\u201312.","journal-title":"J Clin Oncol"},{"key":"111_CR27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-3565(25)28065-X","volume":"163","author":"FM Radzialowski","year":"1968","unstructured":"Radzialowski FM, Bousquet WF. Daily rhythmic variation in hepatic drug metabolism in the rat and mouse. J Pharmacol Exp Ther. 1968;163:229\u201338.","journal-title":"J Pharmacol Exp Ther"},{"key":"111_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/FPC.0b013e3282f12a61","volume":"17","author":"T Takiguchi","year":"2007","unstructured":"Takiguchi T, Tomita M, Matsunaga N, Nakagawa H, Koyanagi S, Ohdo S. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics. 2007;17:1047\u201356.","journal-title":"Pharmacogenet Genomics"},{"key":"111_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"111_CR30","unstructured":"Diekstra MHM, Kl\u00fcmpen HJ, Lolkema MPJK, et al. Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics [abstract no. 4580]. ASCO Annual Meeting; 24\u201326 October 2013; Chicago."},{"key":"111_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/clpt.2012.243","volume":"93","author":"JH Beumer","year":"2013","unstructured":"Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013;93:228\u201330.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0111-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0111-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T20:32:11Z","timestamp":1746045131000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0111-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}